• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Axcella Health Inc. (Amendment)

    9/23/22 4:31:52 PM ET
    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AXLA alert in real time by email
    SC 13D/A 1 d346010dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    AXCELLA HEALTH INC.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    05454B105

    (CUSIP Number)

    Noubar B. Afeyan, Ph.D.

    Flagship Pioneering

    55 Cambridge Parkway, Suite 800E

    Cambridge, MA 02142

    (617) 868-1888

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    September 20, 2022

    (Date of Event Which Requires Filing of Statement on Schedule 13D)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), checking the following box.   ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship VentureLabs IV, LLC

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      WC

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      2,035,830

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      2,035,830

      (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      2,035,830

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      3.9%

    (14)  

      Type of Reporting Person (See Instructions):

     

      OO


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures Fund IV, L.P.

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      WC

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      10,636,233

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      10,636,233

      (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      10,636,233

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      20.2%

    (14)  

      Type of Reporting Person (See Instructions):

     

      PN


    CUSIP No. 05454B105

     

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures Fund IV-Rx, L.P.

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      WC

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      2,004,657

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      2,004,657

    (11)  

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      2,004,657

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      3.8%

    (14)  

      Type of Reporting Person (See Instructions):

     

      PN

     


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures Fund IV General Partner LLC

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      AF

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      12,640,890

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      12,640,890

    (11)  

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      12,640,890

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      24.0%

    (14)  

      Type of Reporting Person (See Instructions):

     

      OO

     


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures Fund 2007, L.P.

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      WC

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      1,761,029

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      1,761,029

      (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      1,761,029

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      3.3%

    (14)  

      Type of Reporting Person (See Instructions):

     

      PN

     


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures 2007 General Partner LLC

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      AF

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      1,761,029

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      1,761,029

      (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      1,761,029

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      3.3%

    (14)  

      Type of Reporting Person (See Instructions):

     

      OO

     


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures Opportunities Fund I, L.P.

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      WC

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      4,465,866

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      4,465,866

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      4,465,866

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      8.5%

    (14)  

      Type of Reporting Person (See Instructions):

     

      PN


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Flagship Ventures Opportunities Fund I General Partner LLC

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      AF

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      4,465,866

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      4,465,866

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      4,465,866

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      8.5%

    (14)  

      Type of Reporting Person (See Instructions):

     

      OO


    CUSIP No. 05454B105

     

      (1)    

      Name of Reporting Persons:

     

      Noubar B. Afeyan, Ph.D.

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions):

     

      (a)  ☐        (b)  ☒

      (3)  

      SEC Use Only:

     

      (4)  

    Source of Funds (See Instructions):

     

      AF

      (5)  

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

     

      ☐

      (6)  

      Citizenship or Place of Organization:

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       (7)    

      Sole Voting Power

     

      0

       (8)  

      Shared Voting Power

     

      18,867,785

       (9)  

      Sole Dispositive Power

     

      0

       (10)  

      Shared Dispositive Power

     

      18,867,785

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      18,867,785

    (12)  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11):

     

      35.8%

    (14)  

      Type of Reporting Person (See Instructions):

     

      IN


    CUSIP No. 05454B105

     

    ITEM 1.

    SECURITY AND ISSUER

    This Amendment No. 3 (this “Amendment”) amends and supplements the Schedule 13D (the “Schedule 13D”) filed by the Reporting Persons (as defined below) on May 23, 2019, as amended, with respect to the common stock, $0.001 par value per share (“Common Stock”), of Axcella Health Inc. (the “Issuer” or the “Company”). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.

     

    ITEM 4.

    PURPOSE OF TRANSACTION

    Item 4 is hereby amended to include the following:

    Securities Purchase Agreement

    On September 20, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Flagship Ventures Fund IV, L.P. (“Flagship Fund IV”) and Flagship Ventures Opportunities Fund I, L.P. (“Flagship Opportunities I,” each a “Purchaser” and together, the “Purchasers”), pursuant to which the Company agreed to sell, and the Purchasers agreed to purchase, unsecured convertible promissory notes in aggregate principal amount of up to $12 million (the “Notes”) in a private placement (the “Private Placement”) with the initial closing occurring on September 20, 2022 (the “Initial Closing” and such date, the “Initial Closing Date”). At the Initial Closing, Flagship Fund IV and Flagship Opportunities I purchased $4,500,000 and $1,500,000 in Notes, respectively. The Company may conduct any number of additional closings (each, including the Initial Closing, a “Closing”) so long as the final Closing occurs on or before the six month anniversary of the Initial Closing Date.

    The Notes mature one year from the date of issuance and bear interest at the rate of 8% per annum payable upon the earlier of (i) voluntary conversion of the Notes in accordance with the terms thereof and (ii) the maturity date. All principal and accrued interest under the Notes (the “Outstanding Balance”) will automatically convert at the Company’s next equity financing (the “Subsequent Financing”), without any action on the part of the Purchasers, into such securities of the Company as are issued in the Subsequent Financing at a conversion price equal to lowest price per share of Common Stock paid by investors in such Subsequent Financing (provided, however, if such Subsequent Financing is not a public offering and the number of securities to be issued in the Subsequent Financing shall exceed 20% of the voting power of the Company outstanding before the issuance of stock or securities convertible into or exercisable for Common Stock, and stockholder approval has not been obtained with respect to Nasdaq Stock Market Rule 5635(d), then the Conversion Price shall be at least the lower of: (i) the closing price of the Common Stock; or (ii) the average closing price of the Common Stock for the five Trading Days immediately preceding the signing of the definitive documentation or pricing of the Subsequent Financing.) Additionally, in the event that the Notes do not automatically convert prior to the six month anniversary of the Initial Closing, then at any time after such six month anniversary, Purchasers holding a majority of the outstanding balance of the Notes may elect to cause the conversion of all of the Notes into such number of shares of Common Stock equal to (i) the Outstanding Balance plus all accrued and unpaid interest thereon divided by (ii) the lower of (a) the closing price of the Common Stock on such conversion date; or (b) the average closing price of the Common Stock for the five Trading Days immediately preceding such conversion date.

    The Purchase Agreement includes customary covenants, representations and warranty provisions for agreements of its kind.

    The foregoing summaries of the Purchase Agreement and Notes are qualified in their entirety by the full text of such agreements, the forms of which are filed herewith as Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated by reference into this Item 4.

     

    ITEM 5.

    INTEREST IN SECURITIES OF THE ISSUER

    Item 5(a)-(c) is hereby amended and restated as follows:

    (a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 52,643,309 outstanding shares of Common Stock as of August 9, 2022, as in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2022.


    CUSIP No. 05454B105

     

    Flagship VentureLabs IV, LLC (“VentureLabs IV”), Flagship Fund IV and Flagship Ventures Fund IV-Rx, L.P. (“Flagship Fund IV-Rx” and together with VentureLabs IV and Flagship Fund IV, the “Flagship IV Funds”) directly hold 2,035,830 shares, 8,600,403 shares and 2,004,657 shares of Common Stock, respectively. Flagship Fund IV, as the manager of VentureLabs IV, may be deemed to beneficially own the shares directly held by VentureLabs IV. Flagship Ventures Fund IV General Partner LLC (“Flagship Fund IV GP”), as the general partner of the Flagship Fund IV Funds, may be deemed to beneficially own the shares directly held by the Flagship Fund IV Funds.

    Flagship Ventures Fund 2007, L.P. (“Flagship Fund 2007”) directly holds 1,761,029 shares of Common Stock. Flagship Ventures 2007 General Partner LLC (“Flagship 2007 GP”), as the general partner of Flagship Fund 2007, may be deemed to beneficially own the shares directly held by Flagship Fund 2007.

    Flagship Opportunities I directly holds 4,465,866 shares of Common Stock. Flagship Ventures Opportunities Fund I General Partner LLC (“Flagship Opportunities GP”), as the general partner of Flagship Opportunities I, may be deemed to beneficially own the shares directly held by Flagship Opportunities I.

    Noubar B. Afeyan, Ph.D., as the sole manager of Flagship Fund IV GP, Flagship Fund 2007 GP and Flagship Opportunities GP, may be deemed to beneficially own the shares directly held by the Flagship IV Funds, Flagship Fund 2007 and Flagship Opportunities I.

    (c) None of the Reporting Persons have effected transactions in the Common Stock of the Issuer during the past 60 days.

     

    ITEM 6.

    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

    The information set forth in Item 4 hereof is incorporated by reference in its entirety into this Item 6.

     

    ITEM 7.

    MATERIAL TO BE FILED AS EXHIBITS

     

    Exhibit 99.1    Joint Filing Agreement (filed herewith).
    Exhibit 99.2    Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 23, 2022).
    Exhibit 99.3    Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 23, 2022).


    CUSIP No. 05454B105

     

    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

    Dated: September 23, 2022

     

    FLAGSHIP VENTURELABS IV, LLC

    By:   Flagship Ventures Fund IV, L.P.
    By:   Flagship Ventures Fund IV General Partner LLC
    By:   /s/ Noubar B. Afeyan, Ph.D.
    Name:   Noubar B. Afeyan, Ph.D.
    Title:   Manager
    FLAGSHIP VENTURES FUND IV, L.P.
    By:   Flagship Ventures Fund IV General Partner LLC
    By:   /s/ Noubar B. Afeyan, Ph.D.
    Name:   Noubar B. Afeyan, Ph.D.
    Title:   Manager

     

    FLAGSHIP VENTURES FUND IV-Rx, L.P.
    By:   Flagship Ventures Fund IV General Partner LLC
    By:   /s/ Noubar B. Afeyan, Ph.D.
    Name:   Noubar B. Afeyan, Ph.D.
    Title:   Manager

     

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
    By:   /s/ Noubar B. Afeyan, Ph.D.
    Name:   Noubar B. Afeyan, Ph.D.
    Title:   Manager
    FLAGSHIP VENTURES FUND 2007, L.P.
    By:   Flagship Ventures 2007 General Partner LLC
    By:   /s/ Noubar B. Afeyan, Ph.D.
    Name:   Noubar B. Afeyan, Ph.D.
    Title:   Manager
    FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC
    By:   /s/ Noubar B. Afeyan, Ph.D.
    Name:   Noubar B. Afeyan, Ph.D.
    Title:   Manager


    CUSIP No. 05454B105

     

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.
    By:   Flagship Ventures Opportunities Fund I General Partner LLC
    By:  

    /s/ Noubar B. Afeyan, Ph.D.

    Name:  

    Noubar B. Afeyan, Ph.D.

    Title:  

    Manager

    FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC
    By:  

    /s/ Noubar B. Afeyan, Ph.D.

    Name:  

    Noubar B. Afeyan, Ph.D.

    Title:  

    Manager

    /s/ Noubar B. Afeyan, Ph.D.
    NOUBAR B. AFEYAN, PH.D.

     

    Get the next $AXLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXLA

    DatePrice TargetRatingAnalyst
    11/16/2021$10.00 → $12.00Buy
    Chardan Capital
    10/12/2021$6.00Outperform
    Noble Capital Markets
    9/22/2021$9.00 → $5.00Buy → Neutral
    Goldman Sachs
    7/30/2021Neutral → Underweight
    JP Morgan
    7/6/2021$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AXLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Axcella Health Inc.

      25-NSE - Axcella Health Inc. (0001633070) (Subject)

      2/15/24 8:54:23 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/22/23 4:30:17 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/19/23 4:45:12 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Koziel Margaret

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:54 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Fehlner Paul

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:17:30 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Hinshaw William

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:21 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axcella Announces Reverse Stock Split Effective September 19, 2023

      – AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on Septembe

      9/14/23 4:30:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Granted Patent for Long COVID Fatigue Treatment

      Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticip

      8/29/23 8:00:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Reports Second Quarter Financial Results and Provides Business Update

      AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 The Company continues to pursue a strategic alternative for stakeholders Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. "Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue is potentially an important step to help people mainta

      8/3/23 7:30:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Financials

    Live finance-specific insights

    See more
    • Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

      Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E. Axcella to host a conference call February 16 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. F

      2/15/23 4:10:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference

      Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities' 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023. Details for Axcella's participation are as follows: Date:   Thursday, February 16, 2023 Time:   11:20 am Eastern Time Webcast:   https://wsw.com/webcast/svb8/axla/1608786 The conference call webcast will be accessible in the Investors & News section on the company's website at www.axcellatx.com. An archive

      2/9/23 4:45:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

      MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial submitted to the FDA Axcella to host a conference call Tuesday, January 24 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U

      1/23/23 4:15:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      9/11/23 8:23:54 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      2/14/23 6:06:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      2/9/23 8:23:46 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

      Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

      4/11/22 6:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations

    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Axcella Health with a new price target

      Chardan Capital reiterated coverage of Axcella Health with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      11/16/21 9:26:58 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Noble Capital Markets initiated coverage on Axcella Health with a new price target

      Noble Capital Markets initiated coverage of Axcella Health with a rating of Outperform and set a new price target of $6.00

      10/12/21 8:46:44 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Axcella Health from Buy to Neutral and set a new price target of $5.00 from $9.00 previously

      9/22/21 6:18:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care